Lumos Diagnostics Holdings Ltd ( ASX:LDX , OTC:LDXHF ) will provide a US commercial update on FebriDx at an investor briefing on October 27, following the planned release of its September-quarter financial results.
The rapid diagnostics company intends to report its results for the three months ended September 30, 2026, representing the first quarter of its 2027 financial year, with a shareholder webinar scheduled for 11am AEDT that day.
Management to outline quarterly performance
Chair Sam Lanyon, chief executive officer Doug Ward, chief financial officer Barrie Lambert and chief commercial officer Paul Kase will lead the briefing.
Management will present an overview of the financial results and discuss FebriDx's commercial activities in the US, followed by a question-and-answer session.
Shareholders and investors can register in advance through the webinar link below. Access details will be sent by email once registration is complete.
https://us02web.zoom.us/webinar/register/WN_1ImXEdmvShqthlL1UxNllw
About Lumos Diagnostics
Lumos develops and manufactures rapid point-of-care diagnostic technologies to help healthcare professionals diagnose and manage medical conditions.
The company provides customised diagnostic test development and manufacturing services, alongside proprietary digital reader platforms.
It also develops, manufactures and commercialises its own branded point-of-care tests targeting infectious and inflammatory diseases.
